Last $1.40 USD
Change Today 0.00 / 0.00%
Volume 793.3K
AVEO On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

aveo pharmaceuticals inc (AVEO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/16/13 - $2.68
52 Week Low
05/28/14 - $1.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

aveo pharmaceuticals inc (AVEO) Related Businessweek News

No Related Businessweek News Found

aveo pharmaceuticals inc (AVEO) Details

AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, a biopharmaceutical company, is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase 1 dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase 2 trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors; and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite. AVEO Pharmaceuticals, Inc. has strategic partnerships with St. Vincent’s Hospital Sydney Limited; Kyowa Hakko Kirin; Biogen Idec, Inc.; OSI Pharmaceuticals, Inc.; Centocor Ortho Biotech Inc.; and Merck & Co., Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

71 Employees
Last Reported Date: 03/13/14
Founded in 2001

aveo pharmaceuticals inc (AVEO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $567.9K
Chief Scientific Officer
Total Annual Compensation: $334.5K
Compensation as of Fiscal Year 2013.

aveo pharmaceuticals inc (AVEO) Key Developments

AVEO Pharmaceuticals, Inc.(NasdaqGS:AVEO) dropped from Russell 2000 Index

AVEO Pharmaceuticals, Inc. will be removed from the Russell 2000 Index.

AVEO Pharmaceuticals, Inc.(NasdaqGS:AVEO) dropped from Russell 3000 Index

AVEO Pharmaceuticals, Inc. will be removed from the Russell 3000 Index.

AVEO Pharmaceuticals, Inc. Announces Executive Changes

On June 19, 2014, the Board of Directors of AVEO Pharmaceuticals, Inc. promoted Matthew Dallas to the position of Vice President, Finance and appointed Mr. Dallas Treasurer as acting principal accounting officer of the company effective as of July 1, 2014. Mr. Dallas, 39, currently has responsibility for the company's Finance, IT, and Facilities functions. He previously served as AVEO's Senior Director of Finance and Director of Financial Planning and Analysis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVEO:US $1.40 USD 0.00

AVEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.43 USD 0.00
Bristol-Myers Squibb Co $48.62 USD +0.11
Exelixis Inc $3.33 USD +0.075
GlaxoSmithKline SAE £12.80 EGP 0.00
Takeda Pharmaceutical Co Ltd ¥4,713 JPY +50.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AVEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVEO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at